Comparison of three activated protein C resistance tests in the risk assessment of venous thrombosis in non-carriers of the factor V Leiden mutation

Thrombosis and Haemostasis

Volumn 95, Issue 4, 2006, Pages 728-734

  Guerrero, Felipe ^a   Arnaud, Catherine ^b   Nguyen, Francoise ^a   Boneu, Bernard ^a   Sié, Pierre ^a,c  

^a CHU RANGUEIL   (France)

^b TOULOUSE UNIVERSITY HOSPITAL   (France)

^c CHU PURPAN   (France)

Author keywords

Activated protein C resistance; Factor V Leiden; Factor VIII; Venous thrombosis

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8; THROMBOPLASTIN;

ACTIVATED PROTEIN C RESISTANCE; ADULT; ARTICLE; BIOASSAY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIAGNOSTIC TEST; FEMALE; GENE MUTATION; HEMODILUTION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTEIN DEPLETION; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; VEIN THROMBOSIS;

ACTIVATED PROTEIN C RESISTANCE; ADULT; BLOOD COAGULATION TESTS; CASE-CONTROL STUDIES; FACTOR V; FEMALE; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; MUTATION; RISK FACTORS; VENOUS THROMBOSIS;

EID: 33645728293     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH05-08-0593     Document Type: Article

References (30)

1. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction ofa cofactor to activated protein C. Proc Natl Acad Sci USA. 1993; 90: 1004-8.
2. Koster T, Rosendaal FR, de Ronde H, et al. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden thrombophilia study. Lancet. 1993; 342: 1503-6.
3. Bertina RM, Koeleman BPC, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7. 4.
4. Cumming AM, Tait RC Fildes S, et al. Development of resistance to activated protein C during pregnancy. Br J Haematol 1995; 90: 725-7.
5. Olivieri O, Friso S, Manzato F, et al. Resistance to activated protein C in healthy women taking oral contraceptives. Br J Hematol 1995; 91: 465-70.
6. Henkens CMA, Bom VJJ, Vander Meer J. Lowered APC sensitivity ratio related to increased factor VIII clotting activity. Thromb Haemost 1995; 74: 1198-9.
7. Kamphuisen PW, Eikenboom JC, Bertina RM. Elevated factor VIII levels and the risk of thrombosis. Arterioscler Thromb Vasc Biol 2001; 21: 731-8.
8. Ehrenforth S, Radkte KP, Scharrer L. Acquired activated protein C resistance in patients with lupus anticoagulants. Thromb Haemost 1995; 74: 797-8.
9. Yamazaki T, Nicolas G, Sorensen K, et al. Molecular basis of quantitative factor V deficiency associated with factor VR2 haplotype. Blood 2002; 100: 2515-21.
10. Castoldi E, Brugge J, Nicolas G, et al. Impaired APC cofactor activity of factor V plays a major role in the APC resistance associated with the factor V Leiden (R 506Q) and R2 (HI 299R) mutations. Blood 2004; 103: 4173-9.
11. Souto JC, Almasy L, Borrell M, et al. Genetic determinants of hemostasis phenotypes in Spanish families. Circulation 2000; 101: 1546-51.
12. Soria J, Almasy L, Souto J, et al. A new locus on chromosome 18 that influences normal variation in activated protein C resistance phenotype and factor VIII activity and its relation to thrombosis susceptibility. Blood 2003; 101: 163-7.
13. Rodeghiero F, Tosetto A. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism. Ann Int Med 1999; 130: 643-50.
14. De Visser MC, Rosendaal FR, Bertina RM. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood 1999; 93: 1271-6.
15. Graf LL, Welsh CH, Qamar Z, et al. Activated protein C resistance assay detects thrombotic risk factors other than factor V Leiden. Am J Clin Pathol 2003; 119: 52-60.
16. Svensson PJ, Zöller B, Dahlbäck B. Evaluation of original and modified APCresistance tests in unselected outpatients with clinically suspected thrombosis and in healthy controls. Thromb Haemost 1997; 77: 332-5.
17. Shen L, Dahlback B. Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa. J Biol Chem 1994; 269: 18735-8.
18. Polack B, Schved JF, Boneu B; Groupe d'Etude sur I'Hemostase et la Thrombose'(GEHT). Preanalytical recommendations of the 'Groupe d'Etude sur l'Hemostase et la Thrombose' (GEHT) for venous blood testing in hemostasis laboratories. Haemostasis 2001; 31: 61-8.
19. Sie P, Caron C, Azam J, et al. Reassessment of von Willebrand factor (VWF), VWF propeptide, factor VIII:C and plasminogen activator inhibitors 1 and 2 during normal pregnancy. Br J Haematol 2003; 121: 897-903.
20. Wells PS, Langlois NJ, Webster MA, et al. Elevated factor VIII is a risk factor for idiopathic venous thromboembolism in Canada - Is it necessary to define a new upper reference range for factor VIII? Thromb Haemost 2005; 93: 842-6.
21. Folsom AR, Cushman M, Tsai MY, et al. A prospective study of venous thromboembolism in relation to factor V Leiden and related factors. Blood 2002; 99: 2720-5.
22. Rosendaal FR, van der Meer FJM, Visser Th, et al. ProC® Global screening test and the risk of thrombosis. Thromb Haemost 1999; 82 (Suppl): 731.
23. Grand'Maison A, Bates SM, Johnston M, et al. ProC Global" a functional screening test that predicts recurrent venous thromboembolism. Thromb Haemost 2005; 93: 600-4.
24. de Ronde H, Bertina RM. Laboratory diagnosis of APCresistance: a critical evaluation of the test and the development of diagnostic criteria. Thromb Haemost 1994; 72: 880-6.
25. Visser MCH, van Hyclama Vlieg A, Tans G, et al. Determinants of the APTT- and ETP-based APC sensitivity tests. J Thromb Haemost 2005; 3: 1488-94.
26. Tripodi A, Negri B, Bertina R, et al. Screening for the FV: Q 506 mutationevaluation of thirteen plasmabased methods for their diagnostic efficacy in comparison with DNA analysis. Thromb Haemost 1997; 77: 436-9.
27. Favaloro EJ, Orsag I, Bulcuya M, et al. A 9-year retrospective assessment of laboratory testing for activated protein C resistance: evolution of a novel approach to thrombophilia investigations. Pathology 2002; 34: 348-55.
28. Favaloro EJ, Mirochnik O, McDonald D. Functional activated protein C resistance assays: correlation with factor V DNA analysis is better with RVVT-than APTT-based assays. Br J Biomed Sci 1999; 56~23-33.
29. Jennings I, Kitchen S, Woods TA, et al. Normalization does not improve between-laboratory agreement but may improve specificity of some assays for activated protein C resistance. Blood Coagul Fibrinolysis 1999; 10: 451-3.
30. Tripodi A, Chantarangkul V, Negri B, et al. Standardization of the APC resistance test. Effects of normalization of results by means of pooled normal plasma. Thromb Haemost 1998; 79: 564-6.